MA56187B1 - Traitements de l'angio-oedème héréditaire - Google Patents

Traitements de l'angio-oedème héréditaire

Info

Publication number
MA56187B1
MA56187B1 MA56187A MA56187A MA56187B1 MA 56187 B1 MA56187 B1 MA 56187B1 MA 56187 A MA56187 A MA 56187A MA 56187 A MA56187 A MA 56187A MA 56187 B1 MA56187 B1 MA 56187B1
Authority
MA
Morocco
Prior art keywords
treatments
hereditary angioedema
hae
demand
relates
Prior art date
Application number
MA56187A
Other languages
English (en)
French (fr)
Other versions
MA56187A (fr
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MA56187A publication Critical patent/MA56187A/fr
Publication of MA56187B1 publication Critical patent/MA56187B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA56187A 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire MA56187B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema
PCT/GB2020/051439 WO2020249977A1 (en) 2019-06-14 2020-06-15 Treatments of hereditary angioedema

Publications (2)

Publication Number Publication Date
MA56187A MA56187A (fr) 2022-04-20
MA56187B1 true MA56187B1 (fr) 2023-09-27

Family

ID=67700145

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56187A MA56187B1 (fr) 2019-07-15 2020-06-15 Traitements de l'angio-oedème héréditaire

Country Status (34)

Country Link
US (2) US20220218680A1 (cg-RX-API-DMAC7.html)
EP (2) EP3982960B1 (cg-RX-API-DMAC7.html)
JP (3) JP7356518B2 (cg-RX-API-DMAC7.html)
KR (1) KR102748728B1 (cg-RX-API-DMAC7.html)
CN (1) CN114126612A (cg-RX-API-DMAC7.html)
AR (1) AR119158A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020293614B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021024664A2 (cg-RX-API-DMAC7.html)
CA (1) CA3142218A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021003244A1 (cg-RX-API-DMAC7.html)
DK (1) DK3982960T3 (cg-RX-API-DMAC7.html)
EA (1) EA202193019A1 (cg-RX-API-DMAC7.html)
ES (1) ES2956471T3 (cg-RX-API-DMAC7.html)
FI (1) FI3982960T3 (cg-RX-API-DMAC7.html)
GB (1) GB201910116D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230696T1 (cg-RX-API-DMAC7.html)
HU (1) HUE063163T2 (cg-RX-API-DMAC7.html)
IL (1) IL288615A (cg-RX-API-DMAC7.html)
LT (1) LT3982960T (cg-RX-API-DMAC7.html)
MA (1) MA56187B1 (cg-RX-API-DMAC7.html)
MD (1) MD3982960T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021014557A (cg-RX-API-DMAC7.html)
MY (1) MY205687A (cg-RX-API-DMAC7.html)
PH (1) PH12021552966A1 (cg-RX-API-DMAC7.html)
PL (1) PL3982960T3 (cg-RX-API-DMAC7.html)
PT (1) PT3982960T (cg-RX-API-DMAC7.html)
RS (1) RS64412B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202113304YA (cg-RX-API-DMAC7.html)
SI (1) SI3982960T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300261T1 (cg-RX-API-DMAC7.html)
TW (1) TW202112370A (cg-RX-API-DMAC7.html)
UA (1) UA129869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020249977A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202110685B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
JP2024505596A (ja) * 2021-02-09 2024-02-06 カルビスタ・ファーマシューティカルズ・リミテッド 遺伝性血管性浮腫の治療
US20250281397A1 (en) 2022-04-27 2025-09-11 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途
WO2025172693A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2025172692A1 (en) 2024-02-13 2025-08-21 Kalvista Pharmaceuticals Limited Oral sebetralstat for the treatment of an attack of hereditary angioedema
WO2026003532A1 (en) 2024-06-28 2026-01-02 Kalvista Pharmaceuticals Limited Sebetralstat for the treatment of anxiety associated with hereditary angioedema

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
RU2712621C2 (ru) 2013-05-23 2020-01-30 Калвиста Фармасьютикалз Лимитед Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201609607D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201910116D0 (en) * 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema

Also Published As

Publication number Publication date
CN114126612A (zh) 2022-03-01
TW202112370A (zh) 2021-04-01
MD3982960T2 (ro) 2023-12-31
MX2021014557A (es) 2022-01-11
EP4282474A3 (en) 2024-02-14
DK3982960T3 (da) 2023-08-21
JP2022536287A (ja) 2022-08-15
US20220218680A1 (en) 2022-07-14
PL3982960T3 (pl) 2024-01-15
HUE063163T2 (hu) 2023-12-28
JP7688078B2 (ja) 2025-06-03
CL2023000639A1 (es) 2023-10-30
SMT202300261T1 (it) 2023-09-06
KR20220024220A (ko) 2022-03-03
LT3982960T (lt) 2023-08-25
HRP20230696T1 (hr) 2023-10-13
RS64412B1 (sr) 2023-09-29
WO2020249977A1 (en) 2020-12-17
GB201910116D0 (en) 2019-08-28
EP3982960A1 (en) 2022-04-20
IL288615A (en) 2022-02-01
NZ782935A (en) 2025-02-28
ZA202110685B (en) 2024-06-26
SI3982960T1 (sl) 2023-10-30
US20260199312A1 (en) 2026-07-16
JP2023166406A (ja) 2023-11-21
ES2956471T3 (es) 2023-12-21
PH12021552966A1 (en) 2022-07-25
MY205687A (en) 2024-11-06
CA3142218A1 (en) 2020-12-17
CL2021003244A1 (es) 2022-09-30
UA129869C2 (uk) 2025-08-27
JP7356518B2 (ja) 2023-10-04
BR112021024664A2 (pt) 2022-05-31
EP3982960B1 (en) 2023-06-28
EP4282474A2 (en) 2023-11-29
AU2020293614B2 (en) 2024-08-15
AR119158A1 (es) 2021-12-01
FI3982960T3 (fi) 2023-08-29
EA202193019A1 (ru) 2022-03-24
JP2025124716A (ja) 2025-08-26
PT3982960T (pt) 2023-09-26
KR102748728B1 (ko) 2024-12-30
AU2020293614A1 (en) 2022-01-27
SG11202113304YA (en) 2021-12-30
MA56187A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
ZA202110685B (en) Treatments of hereditary angioedema
MY153669A (en) Ocular allergy treatments field of the invention
EP3632444A3 (en) Topical lfa-1 antagonists for use in localized treatment of immune related disorders
WO2004080467A3 (en) Method of treating and preventing hyperparathyroidism with vitamin d2 or d4 compounds
WO2006135627A3 (en) Inhibitors of akt activity
WO2006091395A3 (en) Inhibitors of akt activity
PH12021552967A1 (en) Treatments of angioedema
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
AU2010279892A8 (en) Humanized anti-amyloid-b oligomer antibody
MX2026001199A (es) Inhibidores del factor d del complemento para administracion oral
WO2006110638A3 (en) Inhibitors of akt activity
EP4245372A3 (en) Hbv inhibitor and use thereof
NO20061818L (no) Fremgangsmate for a inhibere remnant lipoproteinproduksjon
SE0200198D0 (sv) New use
WO2004054513A3 (en) Methods and compositions for treating and preventing ear infections
NO20070127L (no) Fremgangsmate for behandling av granuloma annulare eller sarkoid
WO2006068796A3 (en) Inhibitors of akt activity
WO2008030260A3 (en) Treatment of variola viral infections using a tissue factor inhibitor
WO2007047205A3 (en) Enzyme inhibitors of pai-1
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
ATE340182T1 (de) Sucroseoctasulphat silber saltz
MX2021009663A (es) Tratamiento del sindrome de pitt-hopkins.
WO2020232330A8 (en) Inhibiting agents for bruton's tyrosine kinase
TNSN07386A1 (en) Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
SE0101762D0 (sv) New use